title: Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
abstract: The efficacy of bendamustine (50 mg/m², days 1-3) plus mitoxantrone (10 mg/m², day 1), every 28 days for up to four courses, was evaluated in a Phase II multicentre trial enrolling 59 patients with relapsed or refractory B-cell chronic lymphocytic leukaemia (CLL). Major toxicities were grade 3/4 leucopenia, thrombocytopenia and infections in 42%, 12% and 12% of patients, respectively. Complete and partial response was achieved in 5/59 and 25/29 patients, respectively (overall response rate, 51%). Median time to progression was 22 months (range 1-49 + ) and median survival 27 months (range 0-49 + ). The combination of bendamustine and mitoxantrone is an active regime in relapsed or refractory CLL.
authors.affiliation: Haematology/Oncology Group Practice, Koblenz, Germany.
authors.forename: Hubert
authors.initials: H
authors.lastname: Köppler
authors.affiliation: Department of Internal Medicine III HELIOS Klinikum, Bad Saarow, Germany.
authors.forename: Harald
authors.initials: H
authors.lastname: Fuss
authors.affiliation: Haematology/Oncology Group Practice, Halle, Germany.
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Hurtz
authors.affiliation: Department of Haematology/Oncology Klinikum, Frankfurt/Oder, Germany.
authors.forename: Owe
authors.initials: O
authors.lastname: Knigge
authors.affiliation: Haematology/Oncology Group Practice, Neuss, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Losem
authors.affiliation: Haematology/Oncology Group Practice, Oldenburg, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Reschke
authors.affiliation: Haematology/Oncology Group Practice, Köln, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Schmitz
authors.affiliation: Haematology/Oncology Group Practice, Koblenz, Germany.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Weide
authors.affiliation: Haematology/Oncology Practice, Weiden, Germany.
authors.forename: Johann
authors.initials: J
authors.lastname: Weiß
authors.affiliation: Department I of Internal Medicine, Centre for Integrated Oncology (CIO) Köln-Bonn, University of Cologne, Cologne, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride; D008942:Mitoxantrone